Skip to content

Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery

Perioperative Continuation of Metformin Therapy in Patients With Typ 2 Diabetes Mellitus Undergoing Non-cardiac Surgery

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04284722
Enrollment
400
Registered
2020-02-26
Start date
2020-02-29
Completion date
2021-04-30
Last updated
2020-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperglycemia, Hyperlactatemia, Metformin, Type 2 Diabetes

Brief summary

Evaluation of the effect of peri-operative continuation of oral metformin therapy on the incidence of perioperative hyperglycemia compared to standard preoperative cessation of oral metformin therapy 24h before surgery.

Detailed description

Surgical procedures cause metabolic stress and can impair glucose control especially in patients with diabetes mellitus, which often results in peri-operative hyperglycemia. Peri-operative hyperglycemia is associated with impaired wound healing, secondary wound infections, endothelial dysfunction, sepsis, prolonged hospital stay and higher mortality. Metformin is still the first line treatment in patients with type 2 diabetes mellitus. Historically it has been stopped before surgery due to fear of hypoglycemia and metformin induced lactic acidosis. However recent studies have suggested that perioperative continuation of metformin might be safe and patients could benefit from more stable preoperative blood sugar levels. Prospective studies evaluating the benefit of continuing oral metformin therapy in the perioperative period are rare. The investigators plan to conduct a prospective, randomized-controlled, unblinded clinical trial where patients with type II diabetes mellitus and oral metformin therapy undergoing non-cardiac surgery will be randomized in either an interventional group or a control group. In the interventional group patients will be instructed to continue their regular metformin dose even on the day of surgery, in contrast to the control group, where the patients will be instructed to stop taking metformin 24h prior to surgery. All other oral anti-diabetic drugs will be paused according to the local anesthesia guidelines. The investigators plan to evaluate whether or not continuation of metformin can reduce the incidence of perioperative hyperglycemia and whether or not it is associated with elevation of blood lactate levels.

Interventions

DRUGMetformin Hydrochloride

Perioperative continuation of oral metformin therapy according to the patient's normal dosage and dosage intervals

Sponsors

Kepler University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-99 years * Diabetes Mellitus Typ 2 * Oral metformin therapy * Non cardiac-surgery * Informed consent

Exclusion criteria

* Insulin therapy * Ambulatory surgery * Preoperative therapy with glucocorticoids (prednisolon or equivalent ≥ 5mg/day for more than 7 days) * Planned postoperative ICU-stay * Advanced renal insufficiency (eGFR \< 45ml/kg/min) * Advanced liver cirrhosis or failure (Child-Pugh B or C) * Alcohol abuse * Pregnancy, * Perioperative administration of contrast dye

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Perioperative Hyperglycemia24 hours pre-op until 24 hours post-opblood glucose \>180mg/dl (10mmol/l) and/or necessity of additive administration of insulin s.c. during the time frame

Secondary

MeasureTime frameDescription
Incidence hypoglycemia24 hours pre-op until 24 hours post-opblood sugar levels \< 70mg/dl (3.9mmol/l)
Perioperative lactate levels24 hours pre-op until 24 hours post-opmediane lactate levels at 4 defined dates: 24h pre-op, intra-op, 2 hours post-op and 24h post-op
Incidence of hyperlactatemia24 hours pre-op until 24 hours post-opblood lactate values \>4mmol/L at least at one of 4 measurement dates: 24h pre-op, intra-op, 2 hours post-op, 24 hours post-op
Perioperative blood glucose control24 hours pre-op until 24 hours post-opmean plasma glucose at 4 defined dates: 24h pre-op, intra-op, 2hours post-op and 24h post-op
Hospitalization Durationup to 4 weeksmedian time period from day of surgery until discharge from hospital
Mortalityup to 4 weeksIn-Hospital mortality
Perioperative renal function24 hours pre-op until 24 hours post-opmedian serum-creatinine value at 24h pre-op and 24h post-op

Contacts

Primary ContactMatthias Noitz, MD
matthias.noitz@kepleruniklinikum.at+43 (0)5 7680 83 - 78171

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026